Christopher Seebruck, MD
Ophthalmology · West Mifflin, PANPI 1598999542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Genentech USA, Inc. at 34.7% of the total. 2025 is the largest year on record at $563, 4.2 times the $135 reported in 2020. That places this record below the midpoint for ophthalmology clinicians in PA, where the typical reported total is $1,202.
Across 62 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$502
- AbbVie$216
- Astellas Pharma US Inc$150
- Regeneron Healthcare Solutions, Inc.$127
- ANI Pharmaceuticals, Inc.$117
- Novartis$112
- plus $223 from 8 others
Across 3 payments — averaging $2497.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7K
What the payments were for
- Food & beverage$1,448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 20 | $502 |
| AbbVie(2 entities) | 10 | $216 |
| Astellas Pharma US Inc | 7 | $150 |
| Regeneron Healthcare Solutions, Inc. | 5 | $127 |
| ANI Pharmaceuticals, Inc. | 4 | $117 |
| Novartis | 5 | $112 |
| Harrow Eye, LLC | 1 | $39 |
| Bausch & Lomb Americas Inc. | 2 | $35 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $31 |
| Biogen | 2 | $30 |
| Ocular Therapeutix, Inc. | 1 | $27 |
| Genentech, Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $20 |
| Spark Therapeutics, Inc. | 1 | $16 |
How this compares
$1,448 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 26 | $16,916 |
| RestasisCyclosporine | 16 | $13,469 |
| LumiganBimatoprost | 11 | $6,248 |
| RhopressaNetarsudil Mesylate | 12 | $5,053 |
| Prednisolone Acetate | 147 | $4,311 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,278 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,059 |
| Latanoprost | 88 | $768 |
| Ciprofloxacin Hcl | 63 | $650 |
| Brimonidine Tartrate | 24 | $622 |
| Ketorolac Tromethamine | 31 | $431 |
| Dorzolamide Hcl | 25 | $344 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $341 |
| Timolol Maleate | 43 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $216 | $19,71727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in West Mifflin
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.